@article{ab18fe8702f7480185158bdf0a88321b,
title = "Impact of diabetes mellitus on acute outcomes of percutaneous coronary intervention in chronic total occlusions: insights from a US multicentre registry",
abstract = "Aim: To examine the impact of diabetes mellitus on procedural outcomes of patients who underwent percutaneous coronary intervention for chronic total occlusion. Methods: We assessed the impact of diabetes mellitus on the outcomes of percutaneous coronary intervention for chronic total occlusion among 1308 people who underwent such procedures at 11 US centres between 2012 and 2015. Results: The participants{\textquoteright} mean ± sd age was 66 ± 10 years, 84% of the participants were men and 44.6% had diabetes. As compared with participants without diabetes, participants with diabetes were more likely to have undergone coronary artery bypass graft surgery (38 vs 31%; P = 0.006), and to have had previous heart failure (35 vs 22%; P = 0.0001) and peripheral arterial disease (19 vs 13%; P = 0.002). They also had a higher BMI (31 ± 6 kg/m2 vs 29 ± 6 kg/m2; P = 0.001), similar Japanese chronic total occlusion scores (2.6 ± 1.2 vs 2.5 ± 1.2; P = 0.82) and similar final successful crossing technique: antegrade wire escalation (46 vs 47%; P = 0.66), retrograde (30 vs 28%; P = 0.66) and antegrade dissection re-entry (24 vs 25%; P = 0.66). Technical (91 vs 90%; P = 0.80) and procedural (89 vs 89%; P = 0.93) success was similar in the two groups, as was the incidence of major adverse cardiac events (2.2 vs 2.5%; P = 0.61). Conclusions: In a contemporary cohort of people undergoing percutaneous coronary intervention for chronic total occlusion, nearly one in two (45%) had diabetes mellitus. Procedural success and complication rates were similar in people with and without diabetes.",
author = "Martinez-Parachini, {J. R.} and A. Karatasakis and D. Karmpaliotis and K. Alaswad and Jaffer, {F. A.} and Yeh, {R. W.} and M. Patel and J. Bahadorani and A. Doing and Nguyen-Trong, {P. K.} and Danek, {B. A.} and J. Karacsonyi and A. Alame and Rangan, {B. V.} and Thompson, {C. A.} and S. Banerjee and Brilakis, {E. S.}",
note = "Funding Information: D.K. has served on speaker bureaus for Abbott Vascular, Medtronic and Boston Scientific. K.A. has received consulting fees from Terumo and Boston Scientific and has served as a consultant for Abbott Laboratories. F.A.J. has served as a consultant to Boston Scientific, Siemensand Merck, and received non-financial research support from Abbott Vascular, and a research grant from National Institutes of Health (HL-R01-108229). R.W.Y. has received a Career Development Award (1K23HL118138) from the National Heart, Lung, and Blood Institute. B.V.R. has received research grants from InfraReDx and the Spectranetics Corporation. C.A.T. is an employee of Boston Scientific. Dr. Banerjee has received research grants from Gilead and the Medicines Company, has served as a consultant/speaker and received honoraria from Covidien and Medtronic, and has ownership in MDCARE Global (spouse) and intellectual property in HygeiaTel. E.S.B. has received consulting/speaker honoraria from Abbott Vascular, Asahi, Cardinal Health, Elsevier, GE Healthcare and St Jude Medical, has received research support from Boston Scientific and InfraRedx and is married to an employee of Medtronic. The REDCap tools used for the study were supported by CTSA National Institutes of Health (NIH) Grant UL1-RR024982. Publisher Copyright: {\textcopyright} 2016 Diabetes UK",
year = "2017",
month = apr,
day = "1",
doi = "10.1111/dme.13272",
language = "English (US)",
volume = "34",
pages = "558--562",
journal = "Diabetic Medicine",
issn = "0742-3071",
publisher = "Wiley-Blackwell",
number = "4",
}